Home » Stocks » RMTI

Rockwell Medical, Inc. (RMTI)

Stock Price: $1.43 USD -0.03 (-2.05%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $1.39 -0.04 (-2.80%) Jan 26, 6:14 PM
Market Cap 133.81M
Revenue (ttm) 62.52M
Net Income (ttm) -29.53M
Shares Out 71.81M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $1.43
Previous Close $1.46
Change ($) -0.03
Change (%) -2.05%
Day's Open 1.47
Day's Range 1.35 - 1.48
Day's Volume 2,672,934
52-Week Range 0.84 - 3.57

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Rockwell Medical (RMTI) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 1 week ago

China is a sizable and growing market, with more than 600,000 patients receiving hemodialysis annually China is a sizable and growing market, with more than 600,000 patients receiving hemodial...

GlobeNewsWire - 3 weeks ago

WIXOM, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment...

Seeking Alpha - 2 months ago

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -42.86% and -12.18%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...

Seeking Alpha - 2 months ago

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q2 2020 Results - Quick Version Earnings Call Transcript

Benzinga - 2 months ago

Shares of Rockwell Medical (NASDAQ:RMTI) fell 2.17% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 16.67% over the past year to ($0.10...

GlobeNewsWire - 2 months ago

- Ended the quarter with $67.3 million in cash, cash equivalents and investments-

Zacks Investment Research - 2 months ago

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

WIXOM, Mich., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatment...

GlobeNewsWire - 3 months ago

WIXOM, Mich., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment...

GlobeNewsWire - 4 months ago

-New indications for FPC platform provide significant growth opportunity-

GlobeNewsWire - 4 months ago

WIXOM, Mich., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatm...

Zacks Investment Research - 4 months ago

Rockwell Medical (RMTI) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

GlobeNewsWire - 4 months ago

WIXOM, Mich., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatm...

GlobeNewsWire - 4 months ago

Sizable and growing market opportunity with over 78,000 patients receiving hemodialysis annually Sizable and growing market opportunity with over 78,000 patients receiving hemodialysis annually

GlobeNewsWire - 4 months ago

WIXOM, Mich., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatm...

Seeking Alpha - 5 months ago

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 23.08% and 0.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

-Q2 2020 revenue of $15.9 million-

GlobeNewsWire - 7 months ago

WIXOM, Mich., June 10, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia mana...

GlobeNewsWire - 8 months ago

WIXOM, Mich., May 26, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia manag...

Seeking Alpha - 8 months ago

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 0.00% and 0.96%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 9 months ago

There could be a reason penny stocks trade for under $5, but the returns can be monstrous if there's even minor share price appreciation.

Other stocks mentioned: EVRI, GERN, MNLO, ORBC, PLUG, SELB
GlobeNewsWire - 9 months ago

WIXOM, Mich., March 31, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to transforming anemia mana...

GlobeNewsWire - 9 months ago

– Enhances Triferic platform by providing patients with greater access to Rockwell Medical’s innovative therapeutic by expanding administration options for clinicians –

GlobeNewsWire - 10 months ago

WIXOM, Mich., March 20, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia mana...

GlobeNewsWire - 10 months ago

First $22.5 million tranche funded at closing First $22.5 million tranche funded at closing

Seeking Alpha - 10 months ago

Rockwell Medical, Inc. (RMTI) CEO Stuart Paul on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 8.33% and -6.47%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the st...

GlobeNewsWire - 10 months ago

WIXOM, Mich., March 11, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia mana...

GlobeNewsWire - 10 months ago

No Stockholder Action Required at This Time No Stockholder Action Required at This Time

GlobeNewsWire - 10 months ago

-- Continued progress for Triferic® portfolio ---- 77% increase in the number of clinics under contract -- WIXOM, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI...

GlobeNewsWire - 11 months ago

WIXOM, Mich., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia manag...

GlobeNewsWire - 11 months ago

WIXOM, Mich., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia manag...

GlobeNewsWire - 1 year ago

- Sizable and growing market opportunity with 120,000+ patients receiving hemodialysis annually – - Sizable and growing market opportunity with 120,000+ patients receiving hemodialysis annually –

GlobeNewsWire - 1 year ago

WIXOM, Mich., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to transforming anemia manag...

GlobeNewsWire - 1 year ago

– Company adds experienced medical executive to management team and leading nephrologists to Medical Advisory Board –

Seeking Alpha - 1 year ago

Rockwell Medical, Inc. (RMTI) CEO Stuart Paul on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 20.00% and 0.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the s...

GlobeNewsWire - 1 year ago

– Company reports first full quarter of results for Dialysate Triferic, highlighted by greater than 75% conversion rate from Triferic Evaluation Program –  – Signs leading East Coast academic ...

Zacks Investment Research - 1 year ago

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

WIXOM, Mich., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to improving outcomes for pa...

GlobeNewsWire - 1 year ago

–  Encouraging progress for Triferic® portfolio – – Conference call at 8:30 am ET on Friday, October 25, 2019 –

GlobeNewsWire - 1 year ago

WIXOM, Mich., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, is sch...

GlobeNewsWire - 1 year ago

WIXOM, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to improving outcomes for p...

Seeking Alpha - 1 year ago

After a tumultuous 2018, Rockwell Medical, Inc. has just launched Dialysate Triferic for the treatment of anemia in hemodialysis patients.

GlobeNewsWire - 1 year ago

WIXOM, Mich., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, is sche...

About RMTI

Rockwell Medical operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis. It is also developing an intravenous formulation of Triferic for use by hemodi... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jan 27, 1998
CEO
Russell Ellison
Employees
299
Stock Exchange
NASDAQ
Ticker Symbol
RMTI
Full Company Profile

Financial Performance

In 2019, RMTI's revenue was $61.30 million, a decrease of -3.29% compared to the previous year's $63.39 million. Losses were -$34.13 million, 6.23% more than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for RMTI stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 389.51% from the latest price.

Price Target
$7.00
(389.51% upside)
Analyst Consensus: Buy